Twist Bioscience
NASDAQ: TWSTSouth San Francisco, US · Founded 2013 · Delaware corporation · 1,308 employees on LinkedIn · Public · 14 known investors
Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals. The platform enables faster and more affordable DNA synthesis at scale with customizable high-throughput capabilities.
Also known as Twist · TWST
Founders & leadership
Twist Bioscience was founded in 2013 by Emily Marine Leproust, William Charles Banyai, Bill James Peck, and Emily Leproust.


Board


Investors · 14
Reported raises · per SEC filings
Form D private placements$260.8M disclosed across 7 rounds · 2013–2018
▶$50MraisedApr 2018 · 1 investors · BiotechnologyRule 506(b)
- Keith CrandellDirector
- Paul ConleyDirector
- Bob RagusaDirector
- Minqi LiDirector
- Rob ChessDirector
- William BanyaiExecutive Officer, Director
- Fred CravesDirector
- Bill PeckExecutive Officer
- Emily Marine LeproustExecutive Officer, Director
- Offering amount
- $85M
- Amount sold
- $50M
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$74.9MraisedDec 2017 · 63 investors · BiotechnologyRule 506(b)
- Keith CrandellDirector
- Bill PeckExecutive Officer
- Paul ConleyDirector
- Emily Marine LeproustExecutive Officer, Director
- Bob RagusaDirector
- Rob ChessDirector
- Fred CravesDirector
- William BanyaiExecutive Officer, Director
- Offering amount
- $75M
- Amount sold
- $74.9M
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$2.6MraisedApr 2016 · 46 investors · BiotechnologyRule 506(b)
- Keith CrandellDirector
- William Charles BanyaiExecutive Officer, Director
- Paul ConleyDirector
- Solange GlaizeExecutive Officer
- Rob ChessDirector
- Fred CravesDirector
- Bill James PeckExecutive Officer
- Emily Marine LeproustExecutive Officer, Director
- Nick NaclerioDirector
- Offering amount
- $2.6M
- Amount sold
- $2.6M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$61MraisedJan 2016 · 35 investors · BiotechnologyRule 506(b)
- Emily Marine LeproustExecutive Officer, Director, Promoter
- William Charles BanyaiExecutive Officer, Director, Promoter
- Paul ConleyDirector
- Nick NaclerioDirector
- Rob ChessDirector
- Keith CrandellDirector
- Fred CravesDirector
- Bill James PeckExecutive Officer, Promoter
- Offering amount
- $61M
- Amount sold
- $61M
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$37MraisedJun 2015 · 28 investors · BiotechnologyRule 506(b)
- Keith CrandellDirector
- Paul ConleyDirector
- Fred CravesDirector
- Emily Marine LeproustExecutive Officer, Director, Promoter
- William Charles BanyaiExecutive Officer, Director, Promoter
- Bill James PeckExecutive Officer, Promoter
- Rob ChessDirector
- Offering amount
- $37M
- Amount sold
- $37M
- First sale
- May 2015
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$26MraisedMay 2014 · 24 investors · BiotechnologyRule 506(b)
- William Charles BanyaiExecutive Officer, Director
- Keith CrandellDirector
- Bill James PeckExecutive Officer
- Paul ConleyDirector
- Fred CravesDirector
- Emily Marine LeproustExecutive Officer, Director
- Offering amount
- $26.5M
- Amount sold
- $26M
- First sale
- May 2014
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$9.1MraisedFeb 2014 · 16 investors · Other TechnologyRule 506(c)
- Keith CrandellDirector
- Emily Marine LeproustExecutive Officer, Director
- William Charles BanyaiExecutive Officer, Director
- Paul ConleyDirector
- Bill James PeckExecutive Officer
- Offering amount
- $9.3M
- Amount sold
- $9.1M
- First sale
- Jul 2013
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Twist Bioscience is a biotechnology company headquartered in South San Francisco, California that manufactures synthetic DNA and DNA-derived products for customers across a range of industries [7]. Its catalog spans arrayed and pooled genes (clonal genes, gene fragments, gene pools, multiplexed gene fragments), oligo pools and cloned oligo pools, and variant libraries including TCR libraries, combinatorial variant libraries, site saturation libraries and enzyme screening kits [0][1].
A second major product line covers next-generation sequencing (NGS) workflows: target enrichment panels (custom panels, Exome 2.0, DNA comprehensive genomic profiling, RNA Exome, Human Methylome), hybridization solutions and enzymes such as TrueAmp Polymerase Mix, library preparation kits (TrueAmp, PCR-free WGS, cfDNA, RNA, EM-seq v2 methylation detection), and synthetic controls such as cfDNA pan-cancer reference standards and respiratory and monkeypox virus controls [0][1]. Through Twist Biopharma Solutions the company offers antibody discovery and engineering services, including in vitro and in vivo discovery, antibody optimization, production and characterization, bispecific and VHH antibodies, plus pipeline licensing and partnerships [3][4]. The site also lists IVDR solutions, an ordering platform with a Twist API and procurement integrations, and an NGS ProLab certified services program [0][1].
Business model
Twist sells synthetic DNA products and NGS reagents/kits directly through an online ordering platform (including API and procurement-system integrations) and via channel partners and distributors, and additionally provides antibody discovery and characterization services to biopharma customers under partnership, collaboration and licensing arrangements [0][1][3].
Traction
Wikipedia cites revenue of $54.2 million for 2019 and approximately 400 employees [7]. Company materials cite antibody discovery throughput of more than 6,000 IgGs per week with full characterization data in as few as 15 days [0][1][3].
Latest developments
Recent or newly flagged products on the company site include the TrueAmp Library Preparation Kit, cfDNA Library Prep Kit and cfDNA Pan-Cancer Reference Standard v2, EM-seq v2 methylation detection system, Human Methylome panel, multiplexed gene fragments, TCR libraries, enzyme screening kits and an MRD Express offering [0][1].
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Described as a synthetic biology company manufacturing DNA sequences and a manufacturer of synthetic DNA products serving a wide range of industries [6][7]; it is a component of the Russell 2000 index [7].
Technology
The company's offering is built on synthetic DNA manufacturing, supported by sequence design tools including a Sequence Design Workbench, Manufacturability Analyzer, Codon Optimizer and vector toolbox, and by proprietary reagents such as the TrueAmp library preparation chemistry described as delivering uniformity across GC-rich, AT-rich and repeat-dense regions [0][1]. In May 2021 Twist and Genome Project-Write launched a CAD platform for whole genome design intended to automate workflows spanning plasmids to megabase-scale genomes [7].
Go-to-market
Direct e-commerce ordering with sign-in accounts, an API and procurement integrations, an "NGS ProLab" certified service provider program, and a network of channel partners and distributors; multilingual site support (English, Chinese, Japanese, Spanish) indicates international selling [0][1].
Research and clinical customers in synthetic biology, cancer research and clinical oncology (including liquid biopsy and minimal residual disease), infectious disease research, agricultural biotechnology, drug discovery and AI-driven drug discovery [0][1][4].
Geography
Headquartered in South San Francisco, California [6][7]; the customer-facing site is offered in English, Chinese, Japanese and Spanish [0][1].
History
Founded in 2013 by Emily Leproust, Bill Banyai and Bill Peck [7]. Leproust represented the company at a March 2021 tabletop exercise at the Munich Security Conference simulating a weaponized monkeypox outbreak [7]. In May 2021 Twist and Genome Project-Write launched a CAD platform for whole genome design [7]. The company is now publicly traded on Nasdaq as TWST [7].
Risks & controversies
One aggregator source reports a $120M Series D at a $1.5B valuation dated September 2025 with Greylock Partners, Founders Fund and Kleiner Perkins, and total funding of $350M; these figures are internally inconsistent (headline total raised of $120M versus $350M) and conflict with the company's public-market status, so they should be treated as low confidence [6].
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Founder mafia
3 people who came through Twist Bioscience went on to found or lead other companies.
+ 1 more
Competitors · 2
by search overlapCompanies competing with Twist Bioscience for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 2
launches, deals, and filingsTwist Bioscience and Genome Project-Write launched a computer-aided design platform to automate whole genome design workflows, from plasmids to megabase-scale genomes.
Twist Bioscience, represented by Emily Leproust, took part in a tabletop exercise simulating an outbreak of weaponized monkeypox.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
Twist Bioscience to Report Fiscal 2026 Third Quarter Financial Results on Monday, August 3, 2026 - BioSpacebiospace.com · Jul 2026▸Research sources · 8
primary sources listed
- Twist Biosciencetwistbioscience.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Twist Bioscience do?
- Nasdaq-listed synthetic biology company (TWST) manufacturing synthetic DNA, genes, NGS tools and antibody discovery services.
- Who founded Twist Bioscience?
- Twist Bioscience was founded by Emily Marine Leproust, William Charles Banyai, Bill James Peck, Emily Leproust in 2013.
- Who are Twist Bioscience's investors?
- Twist Bioscience's investors include +ND Capital, 3E Bioventures Capital, ARCH Venture Partners, Asset Management Company, Bay City Capital, Black Opal Ventures, Dentsu Ventures, iGlobe Partners and 6 more.
- How much funding has Twist Bioscience raised?
- Twist Bioscience has disclosed $260.8M raised across 7 rounds.
- Is Twist Bioscience publicly traded?
- Yes — Twist Bioscience trades on NASDAQ under the ticker TWST.
- Where is Twist Bioscience headquartered?
- Twist Bioscience is headquartered in South San Francisco, US.




